Your browser doesn't support javascript.
loading
Vanin-1 expression and methylation discriminate pediatric asthma corticosteroid treatment response.
Xiao, Chang; Biagini Myers, Jocelyn M; Ji, Hong; Metz, Kelly; Martin, Lisa J; Lindsey, Mark; He, Hua; Powers, Racheal; Ulm, Ashley; Ruff, Brandy; Ericksen, Mark B; Somineni, Hari K; Simmons, Jeffrey; Strait, Richard T; Kercsmar, Carolyn M; Khurana Hershey, Gurjit K.
Afiliação
  • Xiao C; Division of Asthma Research, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio.
  • Biagini Myers JM; Division of Asthma Research, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio.
  • Ji H; Division of Asthma Research, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio.
  • Metz K; Division of Allergy and Immunology, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio.
  • Martin LJ; Division of Human Genetics, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio.
  • Lindsey M; Division of Asthma Research, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio.
  • He H; Division of Human Genetics, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio.
  • Powers R; Division of Asthma Research, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio.
  • Ulm A; Division of Asthma Research, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio.
  • Ruff B; Division of Asthma Research, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio.
  • Ericksen MB; Division of Asthma Research, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio.
  • Somineni HK; Division of Asthma Research, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio.
  • Simmons J; Division of Hospital Medicine, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio.
  • Strait RT; Division of Emergency Medicine, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio.
  • Kercsmar CM; Division of Pulmonary Medicine, and the Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio.
  • Khurana Hershey GK; Division of Asthma Research, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio. Electronic address: Gurjit.Hershey@cchmc.org.
J Allergy Clin Immunol ; 136(4): 923-31.e3, 2015 Oct.
Article em En | MEDLINE | ID: mdl-25910714
BACKGROUND: There is considerable heterogeneity in asthma treatment response. OBJECTIVE: We sought to identify biomarkers of corticosteroid treatment response in children with asthma and evaluate the utility and mechanistic basis of these biomarkers. METHODS: Children (5-18 years) presenting to the emergency department with an acute asthma exacerbation were recruited and followed during hospitalization. Nasal epithelial cells were collected on presentation to the emergency department (T0) and 18 to 24 hours later (T1), and T1/T0 gene expression ratios were analyzed to identify genes associated with good and poor corticosteroid treatment response phenotypes. The utility of these genes in discriminating between systemic corticosteroid treatment response groups was then tested prospectively in a new cohort of patients. A gene candidate (vanin-1 [VNN1]) that consistently distinguished good versus poor response phenotypes was further studied in an experimental asthma model, and VNN1 promoter methylation was measured by means of bisulfite pyrosequencing in patients. RESULTS: VNN1 mRNA expression changes were associated with systemic corticosteroid treatment response in children with acute asthma, and VNN1 was required for optimal response to corticosteroid treatment in an experimental asthma model. A CpG site within the VNN1 promoter was differentially methylated between good versus poor treatment response groups, and methylation at this site correlated with VNN1 mRNA expression. CONCLUSIONS: We have identified a biological basis for poor corticosteroid treatment response that can be used to distinguish a subgroup of asthmatic children who respond poorly to systemic corticosteroid treatment. VNN1 contributes to corticosteroid responsiveness, and changes in VNN1 nasal epithelial mRNA expression and VNN1 promoter methylation might be clinically useful biomarkers of treatment response in asthmatic children.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Asma / Corticosteroides / Biomarcadores Farmacológicos / Amidoidrolases / Mucosa Nasal Tipo de estudo: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Animals / Child / Child, preschool / Female / Humans / Male Idioma: En Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Asma / Corticosteroides / Biomarcadores Farmacológicos / Amidoidrolases / Mucosa Nasal Tipo de estudo: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Animals / Child / Child, preschool / Female / Humans / Male Idioma: En Ano de publicação: 2015 Tipo de documento: Article